Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling

Abstract One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not pos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of nuclear medicine 2019-01, Vol.18 (1), p.66-68
Hauptverfasser: Simsek, Fikri Selcuk, Akarsu, Saadet, Narin, Yavuz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 68
container_issue 1
container_start_page 66
container_title World journal of nuclear medicine
container_volume 18
creator Simsek, Fikri Selcuk
Akarsu, Saadet
Narin, Yavuz
description Abstract One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUV max ) was 1.5; SUV max lesion/SUV max liver 1.0, and SUV max / SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.
doi_str_mv 10.4103/wjnm.WJNM_11_18
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A570398382</galeid><sourcerecordid>A570398382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c585n-a2c2894c88f09a59e3ea784386db23d0501362e55e8968e753f3a3344c7e44913</originalsourceid><addsrcrecordid>eNp1kkFr3DAQhU1paUKac29FUOjNG8mSLPlSCEuaJqTtpaVHobXHa21syZXkNf331bJJNguNdJCY-eYxM7wse0_wghFML-aNHRa_b79_U4QoIl9lp6TEIqeUFK_Tn3GcE8LESXYewganwwspuHibnVAsBOOcnGZuqS2aATWmbcGDjUZHQIPuzdpqG9EI3owdeN0jC34LKHSgY4fiNDiPWu8GtAKb4JSevGvNKoU0mk3s3BSRsVsdzK5MD2Nv7Ppd9qbVfYDzh_cs-_Xl6ufya3734_pmeXmX11xym-uiLmTFailbXGleAQUtJKOybFYFbTDHhJYFcA6yKiUITluqKWWsFsBYRehZ9nmvO06rAZo6TZZmUKM3g_Z_ldNGHWes6dTabVVJuRBYJIGPDwLe_ZkgRLVxk7epZ1WQUkrCJK8O1Fr3oIxtXRKrBxNqdckFppWkskjU4j9Uug0MpnYWWpPiRwWfnhWkjfexC66fonE2HIMXe7D2LgQP7dOEBKudSdTOJOpgklTx4flinvhHSyTgeg_Mro_gw30_zeBVYu-tm1_SVWWpkpXUDOrRSoexY2dggMMCX-rtH3dF4ok</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2168814859</pqid></control><display><type>article</type><title>Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Thieme Connect Journals Open Access</source><creator>Simsek, Fikri Selcuk ; Akarsu, Saadet ; Narin, Yavuz</creator><creatorcontrib>Simsek, Fikri Selcuk ; Akarsu, Saadet ; Narin, Yavuz</creatorcontrib><description>Abstract One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUV max ) was 1.5; SUV max lesion/SUV max liver 1.0, and SUV max / SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.</description><identifier>ISSN: 1450-1147</identifier><identifier>EISSN: 1607-3312</identifier><identifier>DOI: 10.4103/wjnm.WJNM_11_18</identifier><identifier>PMID: 30774551</identifier><language>eng</language><publisher>A-12, 2nd Floor, Sector 2, Noida-201301 UP, India: Thieme Medical and Scientific Publishers Pvt. Ltd</publisher><subject>Approximation ; Blood ; Case Report ; Computation ; Computed tomography ; Consent ; Cost control ; Fever ; Genetic disorders ; Hepatitis B ; HIV ; Human immunodeficiency virus ; Lactate dehydrogenase ; Lesions ; Liver ; Mediastinum ; Medical imaging ; Neurological disorders ; Patients ; Positron emission ; Proteins ; Sedimentation ; Sheaths ; Studies ; Tumors</subject><ispartof>World journal of nuclear medicine, 2019-01, Vol.18 (1), p.66-68</ispartof><rights>Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon.</rights><rights>COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd.</rights><rights>2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2019 World Journal of Nuclear Medicine 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c585n-a2c2894c88f09a59e3ea784386db23d0501362e55e8968e753f3a3344c7e44913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357707/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357707/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,20870,27901,27902,53766,53768,54562,54590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30774551$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Simsek, Fikri Selcuk</creatorcontrib><creatorcontrib>Akarsu, Saadet</creatorcontrib><creatorcontrib>Narin, Yavuz</creatorcontrib><title>Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling</title><title>World journal of nuclear medicine</title><addtitle>World J Nucl Med</addtitle><description>Abstract One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUV max ) was 1.5; SUV max lesion/SUV max liver 1.0, and SUV max / SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.</description><subject>Approximation</subject><subject>Blood</subject><subject>Case Report</subject><subject>Computation</subject><subject>Computed tomography</subject><subject>Consent</subject><subject>Cost control</subject><subject>Fever</subject><subject>Genetic disorders</subject><subject>Hepatitis B</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Lactate dehydrogenase</subject><subject>Lesions</subject><subject>Liver</subject><subject>Mediastinum</subject><subject>Medical imaging</subject><subject>Neurological disorders</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Proteins</subject><subject>Sedimentation</subject><subject>Sheaths</subject><subject>Studies</subject><subject>Tumors</subject><issn>1450-1147</issn><issn>1607-3312</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>0U6</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kkFr3DAQhU1paUKac29FUOjNG8mSLPlSCEuaJqTtpaVHobXHa21syZXkNf331bJJNguNdJCY-eYxM7wse0_wghFML-aNHRa_b79_U4QoIl9lp6TEIqeUFK_Tn3GcE8LESXYewganwwspuHibnVAsBOOcnGZuqS2aATWmbcGDjUZHQIPuzdpqG9EI3owdeN0jC34LKHSgY4fiNDiPWu8GtAKb4JSevGvNKoU0mk3s3BSRsVsdzK5MD2Nv7Ppd9qbVfYDzh_cs-_Xl6ufya3734_pmeXmX11xym-uiLmTFailbXGleAQUtJKOybFYFbTDHhJYFcA6yKiUITluqKWWsFsBYRehZ9nmvO06rAZo6TZZmUKM3g_Z_ldNGHWes6dTabVVJuRBYJIGPDwLe_ZkgRLVxk7epZ1WQUkrCJK8O1Fr3oIxtXRKrBxNqdckFppWkskjU4j9Uug0MpnYWWpPiRwWfnhWkjfexC66fonE2HIMXe7D2LgQP7dOEBKudSdTOJOpgklTx4flinvhHSyTgeg_Mro_gw30_zeBVYu-tm1_SVWWpkpXUDOrRSoexY2dggMMCX-rtH3dF4ok</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Simsek, Fikri Selcuk</creator><creator>Akarsu, Saadet</creator><creator>Narin, Yavuz</creator><general>Thieme Medical and Scientific Publishers Pvt. Ltd</general><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><scope>0U6</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>P5Z</scope><scope>P62</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>201901</creationdate><title>Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling</title><author>Simsek, Fikri Selcuk ; Akarsu, Saadet ; Narin, Yavuz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c585n-a2c2894c88f09a59e3ea784386db23d0501362e55e8968e753f3a3344c7e44913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Approximation</topic><topic>Blood</topic><topic>Case Report</topic><topic>Computation</topic><topic>Computed tomography</topic><topic>Consent</topic><topic>Cost control</topic><topic>Fever</topic><topic>Genetic disorders</topic><topic>Hepatitis B</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Lactate dehydrogenase</topic><topic>Lesions</topic><topic>Liver</topic><topic>Mediastinum</topic><topic>Medical imaging</topic><topic>Neurological disorders</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Proteins</topic><topic>Sedimentation</topic><topic>Sheaths</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simsek, Fikri Selcuk</creatorcontrib><creatorcontrib>Akarsu, Saadet</creatorcontrib><creatorcontrib>Narin, Yavuz</creatorcontrib><collection>Thieme Connect Journals Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simsek, Fikri Selcuk</au><au>Akarsu, Saadet</au><au>Narin, Yavuz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling</atitle><jtitle>World journal of nuclear medicine</jtitle><addtitle>World J Nucl Med</addtitle><date>2019-01</date><risdate>2019</risdate><volume>18</volume><issue>1</issue><spage>66</spage><epage>68</epage><pages>66-68</pages><issn>1450-1147</issn><eissn>1607-3312</eissn><abstract>Abstract One of the most important benign tumors in neurofibromatosis type 1 (NF1) is plexiform neurofibroma, and there is a risk of developing malignant peripheral nerve sheath tumor (MPNST) throughout life approximately 10%. However lesion characterization by anatomical imaging methods are not possible. Because of that most of cases goes to biopsy. Using of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) for lesion characterization can be helpful in NF1 patients. We aimed to present an example of the efficacy of FDG-PET/CT in distinguishing benign neurofibroma from MPNST. A 6-year-old male patient who had NF1 admitted to emergency service due to high fever. Acute upper respiratory tract infection was diagnosed; antipyretic and abundant fluid intake was suggested. When high fever continued, the patient referred to our hospital on detection of axillary lymphadenopathy. Leukocytosis was detected in patient's blood count. Sedimentation was 54 mm/h, C-reactive protein 166 g/L, and lactate dehydrogenase 276U/L. Blood and throat cultures did not show pathogenic bacteria. In serological tests, VZV-IgG, EBV-VCA-IgG, and CMV-IgG were avidite positive; Hepatitis B Ag, Anti-HIV, Anti-HAV IgG and IgM, Anti-HCV, EBV-VCA IgM, and VZV-IgM were negative. Based on these results, cervical and thoracic contrast-enhanced computed tomography was performed on preliminary diagnosis of MPNST. Solid lesions with rounded margins, large one being 49 mm in size, that extend from superior mediastinum to posterior mediastinum, left axillary region, and left part of neck were detected, and they were surrounding the vascular structures. Since neurofibroma, MPNST, and lymphoma could not be distinguished, patient referred to FDG-PET/CT scanning. In FDG-PET/CT, highest lesion maximum standardized uptake value (SUV max ) was 1.5; SUV max lesion/SUV max liver 1.0, and SUV max / SUV mean liver 1.5. Biopsy from mediastinal and axillary region did not have LN structure and was positive for S-100 immunostaining, and patient was diagnosed as benign neurofibroma. We believe that there is no need for biopsy in lesions considered benign based on FDG-PET/CT parameters.</abstract><cop>A-12, 2nd Floor, Sector 2, Noida-201301 UP, India</cop><pub>Thieme Medical and Scientific Publishers Pvt. Ltd</pub><pmid>30774551</pmid><doi>10.4103/wjnm.WJNM_11_18</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1450-1147
ispartof World journal of nuclear medicine, 2019-01, Vol.18 (1), p.66-68
issn 1450-1147
1607-3312
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357707
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Thieme Connect Journals Open Access
subjects Approximation
Blood
Case Report
Computation
Computed tomography
Consent
Cost control
Fever
Genetic disorders
Hepatitis B
HIV
Human immunodeficiency virus
Lactate dehydrogenase
Lesions
Liver
Mediastinum
Medical imaging
Neurological disorders
Patients
Positron emission
Proteins
Sedimentation
Sheaths
Studies
Tumors
title Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T04%3A49%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20we%20differentiate%20malignant%20peripheral%20nerve%20sheath%20tumor%20from%20benign%20neurofibroma%20without%20invasive%20sampling&rft.jtitle=World%20journal%20of%20nuclear%20medicine&rft.au=Simsek,%20Fikri%20Selcuk&rft.date=2019-01&rft.volume=18&rft.issue=1&rft.spage=66&rft.epage=68&rft.pages=66-68&rft.issn=1450-1147&rft.eissn=1607-3312&rft_id=info:doi/10.4103/wjnm.WJNM_11_18&rft_dat=%3Cgale_pubme%3EA570398382%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2168814859&rft_id=info:pmid/30774551&rft_galeid=A570398382&rfr_iscdi=true